SNDX · Syndax Pharmaceuticals, Inc. · Stock research

Current Thesis

Syndax is a two-drug commercial-stage oncology name whose menin-inhibitor franchise has flipped from launch to accelerating ramp. Combined in-market drug sales cleared $100M in a single quarter for the first time (Q1 2026, reported 2026-05-04), and the narrative leg an investor is buying is the label-expansion move from relapsed/refractory AML into frontline AML a roughly 10x larger patient pool where EHA 2026 data already shows best-in-class remission rates. The stock is up ~88% YoY and coiling just under 52-week-high resistance at $25.59 while sell-side price targets sit far above spot. Near-term the tape is event-driven into the 2026-07-14 R&D Day; the real value inflection is undated frontline data in 2H 2026.

Bullish and bearish views on Syndax Pharmaceuticals, Inc.

The model's bull view on Syndax Pharmaceuticals, Inc. (SNDX), in brief: Q1 2026 total revenue $64.9M, +224% YoY vs $20.0M in Q1 2025 (reported 2026-05-04) a genuine acceleration, not a base effect. The bear view: Shares fell 10.7% on the Q1 print despite the revenue surge a sell-the-news reaction that says the market is scrutinizing the slope of the ramp, not celebrating it. Both cases follow in full.

Bull Case

• Q1 2026 total revenue $64.9M, +224% YoY vs $20.0M in Q1 2025 (reported 2026-05-04) a genuine acceleration, not a base effect.
• Revuforj (revumenib) net product revenue $48.9M in Q1 2026; it is the first and only FDA-approved menin inhibitor, now with two labels: KMT2A-translocated acute leukemia (approved Nov 2024) and R/R NPM1-mutated AML (approved 2025-10-24).
• Niktimvo (axatilimab) total net sales $55.1M in Q1 2026 vs $13.6M a year earlier, co-commercialized with Incyte in chronic GVHD; Syndax books 50% of net commercial profit (~$15.9M collaboration revenue this quarter). Combined franchise > $100M/quarter.
• Frontline signal at EHA 2026 (2026-06-11): 97% composite complete remission in 35 newly-diagnosed NPM1m/KMT2Ar AML patients on revumenib + intensive chemo, 86% MRD-negative. Frontline is roughly 10x the R/R TAM.
• All-oral SAVE regimen posted 88% ORR (37/42) in heavily pretreated R/R AML; shares rose ~5.2% on the readout.
• Analyst targets sit well above ~$24.57 (2026-07-08): median ~$38, HC Wainwright reiterated Buy with a $40 target (2026-06-12), street high $57.
• Balance sheet funds the ramp: cash and short-term investments $352.1M at 2026-03-31; net loss narrowed to $42.7M from $84.8M YoY.

Bear Case

• Shares fell 10.7% on the Q1 print despite the revenue surge a sell-the-news reaction that says the market is scrutinizing the slope of the ramp, not celebrating it.
• Jefferies and Mizuho trimmed price targets citing valuation and possible delays in sales growth for the core oncology franchise.
• A technical downgrade to "Sell" landed after the stock stalled near its 52-week high; price is coiling under resistance, not breaking through it.
• Elevated short interest raises two-way volatility and the risk of sharp reversals on any soft data point.
• $11.8M of royalty-interest expense (Royalty Pharma financing) drags the P&L, and the company remains deeply loss-making.
• Menin-inhibitor competition (Kura Oncology and others) can compress the frontline opportunity that underwrites the premium.
• High-multiple biotech is exposed to the current risk-off macro tied to oil and geopolitics.

Setup & Price Structure

• ~$24.57 (2026-07-08), 52-week range $8.71–$25.59, +88.5% YoY, trading above the 200-day.
• The tell is the ceiling: price is pressed against 52-week-high resistance at $25.59 without a clean break. A daily/weekly close that holds above $25.59 converts the coil into a momentum entry; below it the name is range-bound at the top of a long advance.
• The June–July consolidation base defines trend support near $20; that zone is where the multi-month uptrend structure lives.
• Event risk is immediate the 2026-07-14 R&D Day can resolve direction, and R&D days often disappoint absent new data. Standing aside for a confirmed break above $25.59 is the disciplined entry; chasing into the event without that break is the trap here given the recent sell-the-news and PT trims.

Catalyst Calendar (next 30 days)

• ~2026-08-05 (est.): Q2 2026 earnings (Q1 was 2026-05-04) the sequential run-rate check that decides whether the ramp-slope concern is validated. Earnings blackout applies within 3 trading days of the confirmed date.
• 2H 2026 (undated, tracked): BEAT AML frontline revumenib + venetoclax/azacitidine data; revumenib + gilteritinib R/R FLT3 data; Niktimvo Phase 2 frontline cGVHD and IPF topline.

Elapsed catalysts

• 2026-07-14: R&D Day highlighting late-stage and early-stage programs expect framing on frontline AML (BEAT AML, EVOLVE-2 Phase 3) and Niktimvo expansion. Nearest binary-ish event. _(passed 1d ago)_

What Would Change Our Mind

• Frontline BEAT AML / EVOLVE-2 data reading below the ~90%+ CRc bar EHA 2026 established that removes the label-expansion leg.
• Sequential Revuforj revenue deceleration on the Q2 print, confirming the sell-the-news worry.
• A menin-competitor approval or superior frontline data set that reprices the TAM.
• The oncology-immunology theme flipping to SATURATED mainstream coverage, peak retail sentiment, news flow drying up.
• A weekly close below $20.

Correlation Notes

• Incyte (INCY): Niktimvo co-commercialization partner; INCY's cGVHD commentary and guidance move Syndax's collaboration line directly.
• Menin-inhibitor and AML/heme-onc peers (e.g., Kura Oncology): competitive data readouts set the frontline narrative for the whole cohort.
• XBI/IBB beta: a high-multiple, pre-profit biotech, so broad risk-off in the group can override single-name fundamentals on any given week.